Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry

Daniel J Lovell,Nikolay Tzaribachev,Michael Henrickson,Gabriele Simonini,Thomas A Griffin,Ekaterina Alexeeva,John F Bohnsack,Andrew Zeft,Gerd Horneff,Richard K Vehe,Valda Staņēviča,Stacey Tarvin,Maria Trachana,Ana Quintero del Río,Adam M Huber,Daniel Kietz,Ilonka Orbán,Jason Dare,Ivan Foeldvari,Pierre Quartier,Alyssa Dominique,Teresa A Simon,Alberto Martini,Hermine I Brunner,Nicolino Ruperto,Jurgen Brunner,Taciana Fernandes,Simone Appenzeller,Sheila Oliveira,Maria Teresa Terreri,Nikolay Tzaribachev,Kirsten Minden,Mark Hufnagel,Ivan Foeldvari,Gerd Horneff,Astrid Helling-Bakki,Troels Herlin,Estefania Moreno,Jordi Anton,Pablo Mesa- del-Castillo,Clara Udaondo,Inmaculada Calvo Penades,Pierre Quartier,Karine Brochard,Athimalaipet Ramanan,Maria Trachana,Ilonka Orban,Philip Hashkes,Nicolino Ruperto,Gabriele Simonini,Alma Nunzia Olivieri,Francesco Zulian,Davide Montin,Diego Peroni,Valda Stanevicha,Gabriel Vega Cornejo,Nico Wulffraat,Sylvia Kamphuis,Maria Eliana Paz Gastanaga,Tatiana Miraval,Filipa Oliveira-Ramos,Calin Lazar,Irina Nikishina,Ekaterina Alexeeva,Aleksej Sarychev,Vyacheslav Chasnyk,Lyudmila Grebenkina,Wafaa Mohammed Saad Suwairi,Elena Koskova,Mahmood Ally,Ingrid Louw,Johannes Breedt,Hermine Brunner,Tracy Ting,Janalee Taylor,Jennifer Huggins,Michael Henrickson,Esi Morgan DeWitt,Alexei Grom,Daniel Lovell,Grant Schulert,Jackeline Rodriguez-Smith,Jason Dare,Paula Morris,Sukesh Sukumarain,Marissa Klein Gitelman,Michael Miller,Megan Curran,Risa Alperin,Kaveh Ardalan,Deirdre De Ranieri,Megan Hiskey,Brian Nolan,Beth Chalom,Andy Zelf,Steven Spalding,Denise Costanzo,Robert Rennebohm,Brenda Waugaman,Elizabeth Brodus,Angela Robinson,Sirada Panupattanapong,Dan Kietz,Margalit Rosenkranz,Elaine Cassidy,Kathryn Torok,Dan Kingsbury,Victoria Cartwright,Andrew Lasky,Diane Brown,Andreas Reiff,Bracha Shaham,Katherine Marzan,Linda Wagner-Weiner,Karen Onel,Melissa Tesher,Cuoghi Edens,Terry Moore,Reema Syed,Peri Pepmueller,Paul Tuttle,Austin Dalrymple,Srikanth Barhula,Lance Feller,Mara Horwitz,Matt Justice,James Nocton,Judyann Olson,Calvin Williams,James Versbsy,Dominic Co,Elizabeth Roth-Wojcicki,Colleen Correll,Richard Vehe,Bryce Binstadt,Patricia Hobday,Danielle Brueck,Tom Griffin,Miriah Gillispie-Taylor,Sheetal Vora,Stacey Tarvin,Kathleen O'Neil,Susan Ballinger,Michael Blakley,Thomas Klausmeier,Melissa Oliver,Brandi Stevens,Martha Rodriguez,Ellen Go,John Bohnsack,Christi Inman,Aimee Hersh,Sara Stern,Amy Woodward,Debbie Durkee,Sylvie Fadrhonc Boulva,Karen James,Erin Treemarcki,Donald Goldsmith,Svetlana Lvovich,Dana Toib,Julisa Patel,Rita Jerath,Nirupma Sharma,Lauren Newhall,Ruy Carrasco,Nandini Moorthy,Alexis Boneparth,Ana Quintero,Thomas Graham,Stephanie Spence,Alaina Davis,Alisa Gotte,Jay Mehta,Heather Walters,Zanab Mian,Elizabeth Parkinson,Joyce Hui-Yen,Katherine Steigerwald,Marla Guzman,Beth Gottlieb,Ana Quintero,Connie Whitaker,Leslie Kelly,Ruy Carrasco,Rosie Succimarri,Elizabeth Hazel,Gaelle Chedeville,Sarah Compillo,Claire LeBlance,Lori Tucker,David Cabral,Kristin Houghton,Jamie Guzman,Kim Morishita,Adam Huber,Elizabeth Stringer,Suzanne Ramsey,Bianca Lang,Deborah Levy,Earl Silverman,Heinrike Schmeling,Nicole Johnson,Nadia Luca,Muhammed Dhalla,Philip (Pinchas) Hashkes,

DOI: https://doi.org/10.1093/rheumatology/keae025

2024-01-18

Rheumatology

Abstract:Abstract Objective The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry. Methods The Abatacept JIA Registry (NCT01357668) is an ongoing observational study of children with JIA receiving abatacept; enrolment started in January 2013. Clinical sites enrolled patients with JIA starting or currently receiving abatacept. Eligible patients were assessed for safety (primary end point) and effectiveness over 10 years. Effectiveness was measured by clinical 10-joint Juvenile Arthritis Disease Activity Score (cJADAS10) in patients with JIA over 5 years. As-observed analysis is presented according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Results As of 31 March 2020, 587 patients were enrolled; 569 are included in this analysis (including 134 new users) with 1214.6 patient-years of safety data available. Over 5 years, the incidence rate (IR) per 100 patient-years of follow-up of serious adverse events was 5.52 (95% CI: 4.27, 7.01) and of events of special interest was 3.62 (95% CI: 2.63, 4.86), with 18 serious infections [IR 1.48 (95% CI: 0.88, 2.34)]. As early as month 3, 55.9% of patients achieved cJADAS10 low disease activity and inactive disease (20.3%, 72/354 and 35.6%, 126/354, respectively), sustained over 5 years. Disease activity measures improvement over 5 years across JIA categories. Conclusion Abatacept was well tolerated in patients with JIA, with no new safety signals identified and with well-controlled disease activity, including some patients achieving inactive disease or remission. Trial registration Clinicaltrials.gov, NCT01357668.

rheumatology